佐力药业(300181) - 2022 Q3 - 季度财报

Financial Performance - The company's operating revenue for the third quarter was ¥449,454,503.18, an increase of 18.03% compared to the same period last year[7]. - The net profit attributable to shareholders was ¥69,072,832.17, representing a growth of 53.64% year-on-year[7]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥67,121,875.98, up by 51.04% compared to the previous year[7]. - The company reported a 24.66% increase in operating revenue year-to-date, driven by the strategic focus on its "one body, two wings" strategy and strong sales of the Wuling series[14]. - The company’s diluted earnings per share for the third quarter was ¥0.1135, an increase of 53.59% year-on-year[7]. - The net profit for the current period reached CNY 214,596,952.02, an increase of 52.2% compared to CNY 141,046,881.84 in the previous period[33]. - The total revenue from operating activities was CNY 1,358,686,568.10, up from CNY 1,145,765,464.34, reflecting a growth of 18.6%[36]. - The total profit for the current period was CNY 241,462,425.66, compared to CNY 163,470,420.07, an increase of 47.7%[33]. Assets and Liabilities - The total assets at the end of the reporting period were ¥2,528,233,581.92, a decrease of 8.02% from the end of the previous year[7]. - Total current assets rose to ¥1,010,775,134.74, compared to ¥941,671,002.17, marking an increase of about 7.4%[30]. - Non-current assets decreased to ¥1,517,458,447.18 from ¥1,806,861,179.90, a decline of approximately 16.0%[30]. - Total liabilities increased to ¥808,152,229.37 from ¥765,314,231.14, showing a growth of about 5.7%[30]. - The company's total assets decreased to ¥2,528,233,581.92 from ¥2,748,532,182.07, a reduction of approximately 8.0%[30]. Cash Flow - The cash flow from operating activities for the year-to-date period was ¥193,904,381.17, reflecting a growth of 4.27% compared to the same period last year[15]. - Cash outflow from investment activities increased by 280.74% year-on-year, totaling ¥62,695,000, primarily due to increased fixed asset investments[15]. - The cash flow from operating activities netted CNY 193,904,381.17, slightly up from CNY 185,971,918.34, showing a growth of 5.0%[36]. - Cash outflow from investment activities totaled $356.58 million, an increase from $208.25 million year-over-year[39]. - Net cash flow from investment activities was -$62.70 million, compared to $34.69 million in the previous year[39]. - The net increase in cash and cash equivalents was -$34.86 million, compared to -$19.80 million year-over-year[39]. - The ending balance of cash and cash equivalents was $179.37 million, down from $222.48 million in the previous year[39]. Research and Development - Research and development expenses for the year-to-date period reached ¥50,502,900, an increase of 58.49% year-on-year, indicating a significant investment in R&D[14]. - Research and development expenses increased to CNY 50,502,876.94, compared to CNY 31,864,624.60, marking a rise of 58.5%[33]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 43,301[21]. - The largest shareholder, Yu Youqiang, holds 21.34% of the shares, amounting to 129,890,463 shares[21]. - The major shareholder, Deqing County Cultural Tourism Development Group Co., Ltd., plans to transfer 31,296,821 shares, representing 5.14% of the total share capital, at a price not lower than RMB 10 per share[23]. Acquisitions and Approvals - The company acquired a 48.99% stake in Zhejiang Zoli Baicao Traditional Chinese Medicine Co., Ltd. for RMB 75 million, making it a wholly-owned subsidiary[22]. - The company received approval from the China Securities Regulatory Commission for a specific stock issuance, with the board set to proceed according to regulations[23]. - The company has completed the necessary industrial and commercial change registration related to the acquisition of the subsidiary[22]. Other Financial Metrics - The weighted average return on net assets was 3.31%, an increase of 0.86% compared to the previous year[7]. - The company's sales expenses increased to CNY 625,185,175.62 from CNY 527,256,206.19, reflecting a rise of 18.6%[33]. - The company reported a significant increase in investment income, which rose to CNY 2,184,971.15 from CNY 801,339.44, representing a growth of 172.5%[33]. - The total comprehensive income for the current period was CNY -49,959,988.87, a decrease from CNY 750,851,834.92 in the previous period[35]. - The company reported a decrease in other comprehensive income, with a net amount of CNY -264,556,940.89 compared to CNY 609,804,953.08 in the previous period[33]. Audit and Reporting - The third quarter report was not audited[40]. - The report was issued by the board of directors of Zhejiang Zuoli Pharmaceutical Co., Ltd.[41].